BOSTON— Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Jenny Marlowe, Ph.D., as the Company’s Chief Development Officer. Dr. Marlowe is a seasoned biopharma executive and scientific leader with deep expertise in translational, preclinical development, and preclinical safety across multiple genomic medicine modalities.
“I am thrilled to welcome Jenny to Chroma,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “Jenny joins our team at a pivotal time as we prepare to transition to the clinic. Her leadership, experience, and expertise will be instrumental as we work to bring our most transformative epigenetic editing medicines to patients.”
Dr. Marlowe joins Chroma from Solid Biosciences (previously AvantiBio), where she was the Chief Scientific Officer, leading discovery, research, and translational development. Previously she was Vice President of Preclinical and Translational Development at bluebird bio where she served as Program Lead for Zynteglo, a now approved gene therapy for beta thalassemia. Dr. Marlowe began her career at Novartis, where she held multiple leadership positions including Global Head of Strategic Planning and Communication, Investigative Technology, and Director of Translational Safety Models, Preclinical Safety. Dr. Marlowe holds a Ph.D. in Molecular Toxicology, with an emphasis in cellular and molecular mechanisms of carcinogenesis, from the Department of Environmental Health Sciences at the University of Cincinnati and a B.S. in Zoology from Miami University, Oxford, Ohio and is a long-standing Diplomate of the American Board of Toxicology.
“Chroma’s epigenetic editing platform, which leverages the cell’s endogenous system to durably regulate gene expression without cutting or nicking the DNA, is an incredibly compelling technology for creating breakthrough medicines,” said Dr. Marlowe. “I am excited to join Chroma and eager to focus on advancing this new class of genomic therapies to patients.”
